<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">World Allergy Organ J</journal-id><journal-id journal-id-type="iso-abbrev">World Allergy Organ J</journal-id><journal-title-group><journal-title>The World Allergy Organization Journal</journal-title></journal-title-group><issn pub-type="epub">1939-4551</issn><publisher><publisher-name>World Allergy Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3643560</article-id><article-id pub-id-type="publisher-id">1939-4551-6-S1-P102</article-id><article-id pub-id-type="doi">10.1186/1939-4551-6-S1-P102</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Abstract</subject></subj-group></article-categories><title-group><article-title>Allergic diseases of the skin and drug allergies &#x02013; 2015. Randomized controlled, double blind trial of topical twice weekly fluticasone propionate maintenance treatment to reduce risk of relapse in mild or moderate atopic dermatitis in children</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Rubio</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Martinez-Mir</surname><given-names>Inocencia</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Morales-Olivas</surname><given-names>Francisco J</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Martorell-Aragon&#x000e9;s</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Larrea</surname><given-names>Vicente Palop</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Ses&#x000e9;</surname><given-names>Alejandro Bernalte</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Cerd&#x000e1; Mir</surname><given-names>Juan C</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Mart&#x000ed;n</surname><given-names>Pedro Polo</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Febrer</surname><given-names>Isabel</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Grau</surname><given-names>Laura Aranda</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Cortes</surname><given-names>Inmaculada Llosa</given-names></name><xref ref-type="aff" rid="I10">10</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Tejedor Sanz</surname><given-names>Mar&#x000ed;a Jos&#x000e9;</given-names></name><xref ref-type="aff" rid="I11">11</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Juli&#x000e1; Benito</surname><given-names>Juan C</given-names></name><xref ref-type="aff" rid="I12">12</xref></contrib><contrib contrib-type="author" id="A14"><name><surname>De Laviada</surname><given-names>Teresa &#x000c1;lvarez</given-names></name><xref ref-type="aff" rid="I13">13</xref></contrib><contrib contrib-type="author" id="A15"><name><surname>Planelles Cantarino</surname><given-names>Mar&#x000ed;a Victoria</given-names></name><xref ref-type="aff" rid="I14">14</xref></contrib><contrib contrib-type="author" id="A16"><name><surname>Valiente</surname><given-names>Esther Apolinar</given-names></name><xref ref-type="aff" rid="I15">15</xref></contrib><contrib contrib-type="author" id="A17"><name><surname>Tur</surname><given-names>Mercedes Loriente</given-names></name><xref ref-type="aff" rid="I16">16</xref></contrib><contrib contrib-type="author" id="A18"><name><surname>Abella Bazataqui</surname><given-names>Antonio M</given-names></name><xref ref-type="aff" rid="I17">17</xref></contrib><contrib contrib-type="author" id="A19"><name><surname>Gonzalez</surname><given-names>Irene &#x000c1;lvarez</given-names></name><xref ref-type="aff" rid="I18">18</xref></contrib><contrib contrib-type="author" id="A20"><name><surname>Morales-Carpi</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="I19">19</xref></contrib><contrib contrib-type="author" id="A21"><name><surname>Burches Greu</surname><given-names>Maria Enrriqueta</given-names></name><xref ref-type="aff" rid="I20">20</xref></contrib><contrib contrib-type="author" id="A22"><name><surname>Ferrer Bautista</surname><given-names>Ana B</given-names></name><xref ref-type="aff" rid="I14">14</xref></contrib><contrib contrib-type="author" id="A23"><name><surname>Toledo</surname><given-names>Ra&#x000fa;l Felix</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A24"><name><surname>Laguia</surname><given-names>Dolores Marmeneu</given-names></name><xref ref-type="aff" rid="I16">16</xref></contrib><contrib contrib-type="author" id="A25"><name><surname>Garcia-Martinez</surname><given-names>Victoria E</given-names></name><xref ref-type="aff" rid="I16">16</xref></contrib><contrib contrib-type="author" id="A26"><name><surname>Beltran Marques</surname><given-names>Mar&#x000ed;a Antonia</given-names></name><xref ref-type="aff" rid="I15">15</xref></contrib><contrib contrib-type="author" id="A27"><name><surname>Rodriguez Gracia</surname><given-names>Mar&#x000ed;a Bego&#x000f1;a</given-names></name><xref ref-type="aff" rid="I21">21</xref></contrib><contrib contrib-type="author" id="A28"><name><surname>Martinez-Mir</surname><given-names>Inocencia</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib></contrib-group><aff id="I1"><label>1</label>Clinical Pharmacology Unit, Hospital, Valencia, Spain</aff><aff id="I2"><label>2</label>Direcci&#x000f3;n M&#x000e9;dica-Fundaci&#x000f3;n Hgu, Chguv, Valencia, Valencia, Spain</aff><aff id="I3"><label>3</label>Departamento Farmacolog&#x000ed;a, Universitat De Val&#x000e9;ncia, Valencia, Spain</aff><aff id="I4"><label>4</label>Unidad De Alerg&#x000ed;a Pedi&#x000e1;trica, Chguv, Valencia, Spain</aff><aff id="I5"><label>5</label>Subdirecci&#x000f3;n M&#x000e9;dica Asistencial, Departamento De Salud La Ribera, Valencia, Spain</aff><aff id="I6"><label>6</label>Servicio De Farmacia, Chguv, Valencia, Spain</aff><aff id="I7"><label>7</label>Centro De Salud (CS) Barrio De La Luz, Xirivella, Valencia, Xirivella, Spain</aff><aff id="I8"><label>8</label>Servicio Dermatolog&#x000ed;a, Chguv, Valencia, Spain</aff><aff id="I9"><label>9</label>Centro De Atenci&#x000f3;n Primaria De Pobla De Vallbona. Valencia, Spain</aff><aff id="I10"><label>10</label>Monserrat, Valencia, Monserrat, Spain</aff><aff id="I11"><label>11</label>CS Torrente II, Valencia, Torrent, Spain</aff><aff id="I12"><label>12</label>CS Alzira, Valencia, Alzira, Spain</aff><aff id="I13"><label>13</label>Centro De Salud (CS) Barrio De La Luz, Xirivella, Valencia, Xirivella, Spain</aff><aff id="I14"><label>14</label>Paiporta, Valencia, Paiporta, Spain</aff><aff id="I15"><label>15</label>CS Torrente I, Valencia, Torrent, Spain</aff><aff id="I16"><label>16</label>CS Alacuas, Valencia, Alacuas, Spain</aff><aff id="I17"><label>17</label>Centro De Atenci&#x000f3;n Primaria De Pobla De Vallbona, Valencia, Pobla de Vallbona, Spain</aff><aff id="I18"><label>18</label>CS Burjasot II, Valencia, Burjasot, Spain</aff><aff id="I19"><label>19</label>Picasent, Valencia, Picasent, Spain</aff><aff id="I20"><label>20</label>CS Xirivella, Valencia, Xirivella, Spain</aff><aff id="I21"><label>21</label>CS Auxiliar El Vedat De Torrent, Valencia, Torrent, Spain</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>23</day><month>4</month><year>2013</year></pub-date><volume>6</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">2nd WAO International Scientific Conference (WISC 2012), Abstracts</named-content><named-content content-type="supplement-editor">Ruby Pawankar, Lanny J Rosenwasser and Stephen T Holgate</named-content></supplement><fpage>P102</fpage><lpage>P102</lpage><permissions><copyright-statement>Copyright &#x000a9;2013 Rubio et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Rubio et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.waojournal.org/content/6/S1/P102"/><conference><conf-date>6-9 December 2012</conf-date><conf-name>2nd WAO International Scientific Conference (WISC 2012)</conf-name><conf-loc>Hyderabad, India</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>One of the most troublesome features of atopic dermatitis (AD) is its chronic relapsing nature. The long-term efficacy and potential of corticosteroids to reduce or prevent relapses have only partially been addressed, especially in children. This study was designed to compare an intermittent dosing regimen of fluticasone propionate (FP) cream 0.05% (twice per week) with its vehicle base in reducing the risk of relapse in paediatric subjects with stabilized AD.</p></sec><sec sec-type="methods"><title>Methods</title><p>Randomized controlled, multicentric, double blind trial was conducted<bold>.</bold> Severity of AD was scored by means of the modified Scoring of Atopic Dermatitis system (SCORAD). Children (2-10 years) with mild or moderate AD (SCORAD up to 50; exclusion criteria were &#x0003e;30% affected body surface area and/or head) were enrolled into an Open-label Stabilization Phase (OSP) of up to 2 weeks on twice daily FP. Those children who achieved treatment success (SCORAD&#x0003c;5or&#x02265;75% initial SCORAD) entered the Double-blind Maintenance Phase (DMP). They were randomly allocated to receive FP or vehicle twice weekly on consecutive days for 16 weeks. The primary study endpoint was relapse rate of AD, time to relapse and severity of disease were also studied. Kaplan&#x02013;Meier estimates were calculated to describe the time to relapse distribution. The study protocol was approved by the Ethics Committee and all patients&#x02019; parents provided their written informed consent.</p></sec><sec sec-type="results"><title>Results</title><p>Fifty-four patients (29 girls) entered the OSP (23 mild AD) and 49 (26 girls) continued into the DMP. Mean age was 5.5 (SD2.8) and 5.1 (SD2.3) yrs for FP and vehicle groups, respectively. Four patients withdrew from the DMP (two in the FP group and two in the vehicle group). Patients treated with FP twice weekly had a 2.7 fold lower risk of experiencing a relapse than patients treated with vehicle (relative risk 2.72, SE1.28; p=0.034). FP was also superior to vehicle for delaying time to relapse (Mean 108.4 SD32.5 and Mean 77.4 SD54.6, respectively). Therapy with both treatments was well tolerated.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>This long-term study shows that twice per week FP provides an effective maintenance treatment regimen to control AD through a significantly reduction of the risk of relapse in children with mild and moderate AD.</p><p>Grant ISCIII EC08/00004.</p></sec></body></article>